Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 7Recruiting 6Completed 6Not yet recruiting 5Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 129Breast Neoplasms 113Neoplasms 97Neoplasm Metastasis 78Melanoma 73Leukemia, Myeloid, Acute 69Colorectal Neoplasms 69Prostatic Neoplasms 60Multiple Myeloma 52Lung Neoplasms 52Ovarian Neoplasms 51Squamous Cell Carcinoma of Head and Neck 46Triple Negative Breast Neoplasms 42Recurrence 41Carcinoma, Renal Cell 39Carcinoma, Hepatocellular 39Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 35Brain Neoplasms 34Lymphoma 31Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Leukemia 29Lymphoma, Large B-Cell, Diffuse 28Head and Neck Neoplasms 28Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

Ipilimumab 2Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Diabetes Mellitus, Insulin-Dependent, 12 × 1 year × Clear all
NCT03993379 2025-12-26

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

CytomX Therapeutics

Phase 2 Terminated
3 enrolled 7 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms, Recurrence

NCT03013491 2025-06-17

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

CytomX Therapeutics

Phase 1/2 Terminated
196 enrolled 28 charts
Lymphoid

Diabetes Mellitus, Insulin-Dependent, 12, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡